Put Options

13 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2022

Sep 21, 2023

SELL
$234.96 - $292.55 $19.9 Million - $24.8 Million
-84,800 Reduced 99.76%
200 $56,000
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $19.9 Million - $24.8 Million
-84,800 Reduced 99.76%
200 $56,000
Q3 2021

Sep 21, 2023

BUY
$181.39 - $202.99 $10.9 Million - $12.2 Million
60,000 Added 240.0%
85,000 $15.4 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $10.9 Million - $12.2 Million
60,000 Added 240.0%
85,000 $15.4 Million
Q2 2021

Aug 20, 2021

SELL
$187.49 - $221.1 $464 Million - $547 Million
-2,475,000 Reduced 99.0%
25,000 $5.04 Million
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $464 Million - $547 Million
2,475,000 Added 9900.0%
2,500,000 $5.04 Million
Q1 2021

Sep 21, 2023

BUY
$207.02 - $241.31 $5.13 Million - $5.98 Million
24,800 Added 12400.0%
25,000 $5.37 Million
Q1 2021

May 14, 2021

BUY
$207.02 - $241.31 $2.75 Million - $3.21 Million
13,300 Added 113.68%
25,000 $5.37 Million
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $4.04 Million - $5.01 Million
-20,200 Reduced 63.32%
11,700 $2.78 Million
Q4 2019

Feb 13, 2020

SELL
$166.71 - $223.91 $3.67 Million - $4.93 Million
-22,000 Reduced 40.82%
31,900 $6.99 Million
Q3 2019

Nov 13, 2019

SELL
$166.23 - $187.09 $4.45 Million - $5.01 Million
-26,800 Reduced 33.21%
53,900 $9.13 Million
Q4 2018

Feb 14, 2019

SELL
$151.91 - $192.21 $9.01 Million - $11.4 Million
-59,300 Reduced 42.36%
80,700 $13.4 Million
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $20.4 Million - $23.8 Million
140,000 New
140,000 $23.8 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Jefferies Group LLC Portfolio

Follow Jefferies Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.